Precision Engineering of Extracellular Vesicles as Programmable Carriers for mRNA Therapeutics

Abstract: Messenger RNA (mRNA) therapeutics have rapidly evolved into a transformative modality for treating infectious diseases, cancer, and genetic disorders; however, the clinical translation of these therapeutics remains limited by the need for safe, efficient, and tissue-specific delivery vehicles. Subsequently, extracellular vesicles (EVs) have emerged as a promising next-generation platform due to the associated endogenous biogenesis, intrinsic biocompatibility, low immunogenicity, and natural ability to traverse biological barriers. Thus, this review provides a comprehensive evaluation of the major engineering strategies enabling EV-based mRNA delivery, including exogenous loading methods, endogenous genetic engineering, physical microenvironment-driven enhancement, and hybrid EV–synthetic nanoparticle systems. Moreover, this review summarizes advances in electroporation, lipid-mediated fusion, and chemical/physical loading techniques; programmable endogenous loading platforms leveraging EV-sorting proteins and RNA-binding domains; cargo release mechanisms employing self-cleaving, protease-sensitivity, and optogenetic modules; device- and substrate-based approaches that modulate EV biogenesis and cargo composition. We further highlight emerging hybrid EV systems—particularly fusogenic cubosome–EV constructs—that achieve near-quantitative mRNA encapsulation and improved biodistribution, including enhanced penetration across the blood–brain barrier. Finally, we discuss technological bottlenecks and translational considerations, including scalability, batch variability, long-term mRNA stability, and regulatory challenges associated with biologically derived carriers. Collectively, this review outlines the current landscape and future directions for precision engineering of EVs as programmable, clinically viable carriers for mRNA therapeutics. Keywords: extracellular vesicles, drug loading, mRNA delivery, engineering EV, hybrid EVs

Authors

Institutions

Publication Details

Journal
International Journal of Nanomedicine
Published
2026-05-01
DOI
https://doi.org/10.2147/ijn.s595161
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Precision Engineering of Extracellular Vesicles as Programmable Carriers for mRNA Therapeutics

GyuWon Lee, Jain Koo, Yuseon Shin, Sangyong Jung et al.
International Journal of Nanomedicine
Extracellular vesicles in disease
article

Precision Engineering of Extracellular Vesicles as Programmable Carriers for mRNA Therapeutics

GyuWon Lee, Jain Koo, Yuseon Shin, Sangyong Jung, EK Kim, Junyeong Jo, Hyejoo Yoon, Kyung Taek Oh, Chaemin Lim, Hyun Jin Choi
article en

Abstract

Abstract: Messenger RNA (mRNA) therapeutics have rapidly evolved into a transformative modality for treating infectious diseases, cancer, and genetic disorders; however, the clinical translation of these therapeutics remains limited by the need for safe, efficient, and tissue-specific delivery vehicles. Subsequently, extracellular vesicles (EVs) have emerged as a promising next-generation platform due to the associated endogenous biogenesis, intrinsic biocompatibility, low immunogenicity, and natural ability to traverse biological barriers. Thus, this review provides a comprehensive evaluation of the major engineering strategies enabling EV-based mRNA delivery, including exogenous loading methods, endogenous genetic engineering, physical microenvironment-driven enhancement, and hybrid EV–synthetic nanoparticle systems. Moreover, this review summarizes advances in electroporation, lipid-mediated fusion, and chemical/physical loading techniques; programmable endogenous loading platforms leveraging EV-sorting proteins and RNA-binding domains; cargo release mechanisms employing self-cleaving, protease-sensitivity, and optogenetic modules; device- and substrate-based approaches that modulate EV biogenesis and cargo composition. We further highlight emerging hybrid EV systems—particularly fusogenic cubosome–EV constructs—that achieve near-quantitative mRNA encapsulation and improved biodistribution, including enhanced penetration across the blood–brain barrier. Finally, we discuss technological bottlenecks and translational considerations, including scalability, batch variability, long-term mRNA stability, and regulatory challenges associated with biologically derived carriers. Collectively, this review outlines the current landscape and future directions for precision engineering of EVs as programmable, clinically viable carriers for mRNA therapeutics. Keywords: extracellular vesicles, drug loading, mRNA delivery, engineering EV, hybrid EVs

International Journal of NanomedicineVol. Volume 21
Chungbuk National University (KR), CHA University (KR), Chung-Ang University (KR)
Openalex Percentile: Top 7%
Extracellular vesicles in disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.